<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518280</url>
  </required_header>
  <id_info>
    <org_study_id>FDRT-2020-236-2156</org_study_id>
    <nct_id>NCT04518280</nct_id>
  </id_info>
  <brief_title>The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Locally Advanced Rectal Cancer</brief_title>
  <official_title>A Prospective Phase II Trial of Immunotherapy Combined With Short-course Radiotherapy in Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the combination of immunotherapy of PD-1 antibody and neoadjuvant&#xD;
      short-course radiotherapy in locally advanced rectal cancer (LARC). Patients are randomly&#xD;
      assigned into two prospective cohorts: consolidation cohort and induction cohort.&#xD;
      Consolidation cohort: A total of 65 patients will receive 5*5Gy short-course radiotherapy,&#xD;
      followed by 6 cycles of capecitabine plus oxaliplatin (CAPOX) chemotherapy and PD-1 antibody,&#xD;
      finally receive the total mesorectal excision (TME). Induction cohort: A total of 65 patients&#xD;
      will firstly receive 2 cycles of CAPOX chemotherapy and PD-1 antibody, then receive 5*5Gy&#xD;
      short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody,&#xD;
      finally receive the TME surgery. The rate of pathological complete response (pCR), long-term&#xD;
      prognosis and adverse effects will be analyzed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response rate</measure>
    <time_frame>The pathologic complete response (pCR) rate will be evaluated after surgery, which was scheduled 2-4 weeks after the end of neoadjuvant therapy.</time_frame>
    <description>Rate of pathologic complete response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade 3-4 adverse effects rate</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 5 years</time_frame>
    <description>Rate of chemotherapy, radiotherapy and immunotherapy related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 year disease free survival rate</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.</time_frame>
    <description>Rate of 3 year disease free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 year local recurrence free survival rate</measure>
    <time_frame>From date of randomization until the date of first documented pelvic failure, assessed up to 36 months.</time_frame>
    <description>Rate of 3 year local recurrence free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 year overall survival rate</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 36 months.</time_frame>
    <description>Rate of 3 year overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complications</measure>
    <time_frame>The surgery was scheduled 2-4 weeks after the end of neoadjuvant therapy. And the surgical complications were assessed up to 5 years from the surgery.</time_frame>
    <description>Rate of surgical complications, such as intraoperative hemorrhage, anastomotic leakage, intestinal obstruction, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 10 years</time_frame>
    <description>Quality of life will be evaluated using Quality of Life Scale (range 0-60). It evaluates the quality of life from 12 aspects, including appetite, mental status, sleep quality, fatigue, etc. The higher scores mean a better quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Consolidation cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 65 patients will receive 5*5Gy short-course radiotherapy, followed by 6 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TME surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 65 patients will firstly receive 2 cycles of CAPOX chemotherapy and PD-1 antibody, then receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TME surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 antibody</intervention_name>
    <description>PD-1 antibody (Toripalimab): 240mg d1 q3w</description>
    <arm_group_label>Consolidation cohort</arm_group_label>
    <arm_group_label>Induction cohort</arm_group_label>
    <other_name>Toripalimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine: 1000mg/m2 d1-14 q3w</description>
    <arm_group_label>Consolidation cohort</arm_group_label>
    <arm_group_label>Induction cohort</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin: 130mg/m2 d1 q3w</description>
    <arm_group_label>Consolidation cohort</arm_group_label>
    <arm_group_label>Induction cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Short-course radiotherapy</intervention_name>
    <description>Shor-course radiotherapy: 25Gy/5Fx</description>
    <arm_group_label>Consolidation cohort</arm_group_label>
    <arm_group_label>Induction cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. pathological confirmed adenocarcinoma&#xD;
&#xD;
          2. clinical stage T3-4 and/or N+&#xD;
&#xD;
          3. the distance from anal verge less than 12 cm&#xD;
&#xD;
          4. without distance metastases&#xD;
&#xD;
          5. age 18-70 years old, female and male&#xD;
&#xD;
          6. KPS &gt;=70&#xD;
&#xD;
          7. without previous anti-cancer therapy or immunotherapy&#xD;
&#xD;
          8. with good compliance&#xD;
&#xD;
          9. signed the inform consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. pregnancy or breast-feeding women&#xD;
&#xD;
          2. history of other malignancies within 5 years&#xD;
&#xD;
          3. serious medical illness, such as severe mental disorders, cardiac disease,&#xD;
             uncontrolled infection, etc.&#xD;
&#xD;
          4. immunodeficiency disease or long-term using of immunosuppressive agents&#xD;
&#xD;
          5. baseline blood and biochemical indicators do not meet the following criteria:&#xD;
             neutrophils≥1.5×10^9/L, Hb≥90g/L, PLT≥100×10^9/L, ALT/AST ≤2.5 ULN, Cr≤ 1 ULN&#xD;
&#xD;
          6. DPD deficiency&#xD;
&#xD;
          7. allergic to any component of the therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen Zhang, M.D, PH.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhen Zhang, M.D, PH.D</last_name>
    <phone>18801735029</phone>
    <phone_ext>18801735029</phone_ext>
    <email>zhen_zhang@fudan.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huojun Zhang, M.D, PH.D</last_name>
      <email>mxjtg123@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhiqian Hu, M.D, PH.D</last_name>
      <email>1374162606@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhen Zhang</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhen Zhang, M.D, PH.D</last_name>
      <phone>18801735029</phone>
      <phone_ext>18801735029</phone_ext>
      <email>zhen_zhang@fudan.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuolin Xiang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 15, 2020</study_first_submitted>
  <study_first_submitted_qc>August 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhen Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

